New Milestone in HIV Research: ‘Oslo Patient’ Becomes Tenth Person in Remission
A medical breakthrough in Norway has led to the successful remission of HIV in a patient, marking the tenth such case globally since the landmark “Berlin Patient” was identified in 2009. The case, now known as the “Oslo Patient,” highlights the critical role of a specific genetic mutation in blocking the virus and offers new insights into potential eradication strategies.
.jpg?itok=GBG1XVBI)
The findings, published in Nature Microbiology, were the result of a study led by the Oslo University Hospital with contributions from the IrsiCaixa AIDS Research Institute in Barcelona. This growing body of evidence—moving from a single case to ten—provides researchers with a more robust dataset to understand the mechanisms of HIV cure.
The patient, who was diagnosed with HIV at age 44, underwent a stem cell transplant at age 63 to treat a hematologic cancer known as myelodysplastic syndrome. In a rare turn of events, the compatible donor was the patient’s own brother, who carried the CCR5-delta 32 genetic mutation. This specific mutation is vital because it effectively blocks the virus from entering immune cells.
Following the procedure in 2020, the patient remained under medical supervision and ceased antiretroviral therapy two years later. Four years after stopping the treatment, the virus remains undetectable in his system. This outcome underscores the potential of targeting the CCR5 receptor to stop viral replication.
Despite the success, experts caution that this approach is not a universal solution for all people living with HIV. María Salgado, a researcher at IrsiCaixa and co-author of the study, explained that stem cell transplants are “very aggressive” procedures primarily indicated for blood cancers. She noted that most people with HIV currently enjoy a good quality of life and a life expectancy close to that of the general population thanks to modern antiretroviral treatments.
However, these rare cases serve as a roadmap for future medical innovation. Javier Martínez-Picado, also of IrsiCaixa, stated that these milestones are the result of more than a decade of international research. He emphasized that such cases allow the scientific community to better understand how cure occurs, helping them move toward eradication strategies that could eventually be applied to a broader population.
The ability to achieve viral remission in these specific clinical contexts provides a critical foundation for future therapies, potentially guiding the development of less invasive ways to mimic the effects of the CCR5-delta 32 mutation.
